mdd

Mandy and Ryan discuss Mental Health Care and insurance companies, medical breakthroughs, and LGBTQ+ employment. 

Links to the articles mentioned: 

White House pushes private insurance companies to cover mental health care 

Brain imaging-based biomarker of depression identified 

Equality Rising: LGBTQ+ Workers and the Road Ahead 

To reach the National Suicide Hotline, please call 988. 

Follow us on Facebook and Instagram! 

 
Hosted by Mandy Pope and Ryan Machemehl. Produced by Mandy Pope and Ryan Machemehl. Edited by Ryan Machemehl.  

View Privacy Policy at Buzzsprout.com/Privacy. View Disclaimer at TheGreenestSide.com/Podcast. 

Copyright tgsmedia, LLC. All rights reserved. 

In this episode, Ayesha talked about the FDA approval of Zurzuvae (zuranolone) the first oral tablet for the treatment of postpartum depression (PPD). While the approval is a major win in PPD, as current treatments involve administration by infusion or use of general antidepressants, Zurzuvae developers Biogen and Sage Biotech were banking on getting approval for it in major depressive disorder (MDD). However, the FDA rejected it in MDD and only handed the approval in PPD. Hear more about the drug and the approval/rejection in this episode.

Ayesha also talked about Johnson & Johnson’s latest bankruptcy attempt related to its talc baby powder cases that was shot down by a US Bankruptcy Court. The company said it will appeal the decision as it continues to offer talc claimants a $8.9 billion settlement, which it says is the best way to resolve the cases in a timely and financially equitable manner. This is the company’s second bankruptcy attempt, both of which have been turned down so far. Listen to the full episode to learn more about Johnson & Johnson’s ongoing legal saga.

Read the full articles here:

Zurzuvae Earns Win for Postpartum Depression, Faces Challenges in MDDTalc Litigation Saga Continues: Court Rejects J&J’s Latest Bankruptcy Attempt

For more life science and medical device content, visit the Xtalks Vitals homepage.

Follow Us on Social Media

Twitter: @Xtalks
Instagram: @Xtalks
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured

For those of you who missed it, Jared gave a well-received talk at Be Healthy Utah on April 22nd in Utah. Many people asked for a copy of that talk, so he decided to reproduce it as a podcast. This isn’t that talk, it is new, but it covers the same territory in even more detail.

Mental Health is a mounting issue in America today.  Pharma prescriptions are higher than ever before, more people are in therapy than ever before and more than ever, people are searching for alternatives to those methods. In today’s episode, Jared runs through what he considers to be the foundational things that you should consider to improve your mental health.  You will learn about the gut-brain connection, deficiencies that impact mental health, the value of breath, sleep, water,  sunshine, and more.

Products:

Precision Probiotic Vital Spores

Vital 5 Magnesium Bisglycinate

Vital 5 Ultimate Vitality Multi-Vitamin

BioCoenzymated Active B Complex

Vital 5 Omega 3 + Antioxidants

Ultra Strength RX Omega 3

Sensoril Ashwagandha

Anxiety Release

Vital Sleep

L-Theanine chewables 

Additional Information:

Episode #164: Psychobiotics - Unique Probiotics for Depression, Anxiety and More Part 1

Episode #166: Psychobiotics - Unique Probiotics for Depression Anxiety and More Part 2
Episode #306: The Great Debate in Probiotics: Human Strains vs. Spores

Episode #258: Your Magnesium Users Guide

Episode #264: Jen's Story: How One Woman Fought Through Addiction, Mental and Physical Illness to Find Vitality.

Episode #265: Sleep! Your Guide to Falling Asleep, Staying Asleep and Deeper and More Restful Sleep

Tickets to the Mitten Durch Mental Health Festival

Ogdenite Article

Visit the podcast website here: VitalityRadio.com

You can follow @vitalityradio and @vitalitynutritionbountiful on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!

Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.

See omnystudio.com/listener for privacy information.

See omnystudio.com/listener for privacy information.

In this episode, Greg W. Mattingly, MD, and Vladimir Maletic, MD, have a conversation about the complexities of accurately diagnosing bipolar depression. Bipolar depression can be difficult to differentiate from other psychiatric conditions, such as unipolar depression, depression with mixed features, ADHD, PTSD, and anxiety. This differential is made more challenging in that patients with bipolar depression often have psychiatric comorbidities with overlapping symptomology. Listen as the 2 psychiatrists share their insights on how to act as detectives and weed through clues from current symptoms, past symptoms, and family history to reach an accurate diagnosis. 

Presenters:

Greg W. Mattingly, MD
Associate Clinical Professor Psychiatry
Washington University School of Medicine
St Louis, Missouri
President
St Charles Psychiatry Associates
St Charles, Missouri

Vladimir Maletic MD
Clinical Professor
Department of Psychiatry
USC School of Medicine
Greenville, South Carolina

This content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.

For more programs in this series, visit: 
https://bit.ly/3TClDqb

In this episode, Ayesha discussed the FDA approval of Axsome Therapeutics’ rapid-acting oral treatment Auvelity for the treatment of major depressive disorder (MDD). The approval makes Auvelity the first and only rapid-acting oral medication for depression, and the first and only oral NMDA receptor antagonist approved for MDD. Hear more about the approval, including clinical trial data showing the treatment can take effect in as little as one week, and how it is the first antidepressant approved in over 60 years that has a new mechanism of action.

Ayesha shared news about another significant FDA approval for a gene therapy to treat transfusion-dependent beta thalassemia. Bluebird bio was awarded the approval for its gene therapy Zynteglo (beti-cel), which is a one-time treatment for the rare blood disorder. Hear more about the therapy, some of the setbacks bluebird has had to face on the road to its approval and why the treatment has a steep price tag.

Read the full articles here:

Axsome’s Auvelity Wins FDA Approval as First Rapid-Acting Oral Treatment for Depression

Bluebird’s $2.8M Gene Therapy Zynteglo Wins Landmark FDA Approval for Beta Thalassemia

For more life science and medical device content, visit the Xtalks Vitals homepage.

Follow Us on Social Media

Twitter: @Xtalks
Instagram: @Xtalks
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Today, I am attempting to redefine the podcast and figure out where the show should go. Let's talk about physical health, mental health, exhaustion and the overwhelming march of life. Help me out and feel free to give some ideas of where you'd like to see the podcast go :). Message & follow me on Instagram @DeadEnConvos

This week, MG was abandoned and left alone to the demise of her own thoughts. Yikes! Buckle up, because this one's a doozy with endless rabbit holes and unfinished thoughts as she tries to solve the meaning of  life in a forty-minute episode. **Video version also available on youtube!***

In this episode, Roger McIntyre, MD, FRCPC, and Sanjay Mathew, MD, discuss choosing the right treatment in bipolar depression. They review patient assessment and differential diagnosis for bipolar depression, describe various screening tools, examine evidence-based pharmacotherapies, consider the role of adjunctive antidepressants, neuromodulation, light therapy, and psychological treatments, and explore future directions in bipolar depression treatment.  

Presenters:

Sanjay J. Mathew, MD
Professor and Vice Chair for Research
Psychiatry and Behavioral Sciences
Baylor College of Medicine
Houston, Texas

Roger McIntyre, MD, FRCPC
Professor of Psychiatry and Pharmacology
Department of Psychiatry/Pharmacology
University of Toronto
Head, Mood Disorders Psychopharmacology Unit
Department of Psychiatry
Toronto, Canada

Link to full program:
https://bit.ly/3syJzh2

In this episode, the editorial team had the opportunity to speak with Dr. Brett Wingeier, CEO of neuromodulation MedTech company Magnus Medical about the company’s Magnus System for the treatment of major depressive disorder (MDD). The neurostimulation device received breakthrough device designation from the US Food and Drug Administration (FDA) last month. The team heard from Dr. Wingeier about the challenges of treating depression and how neuromodulation shows clinical effectiveness for patients. Given this, he explained how the company decided to develop the Magnus System and described how it works. As a 20-year veteran in the field of neuromodulation, hear Dr. Wingeier’s insights into how the field continues to grow. 

Read the full article here: 

Magnus Medical’s Neurostimulation Technology Granted FDA Breakthrough Device Designation 

For more life science and medical device content, visit the Xtalks Vitals homepage.

Follow Us on Social Media

Twitter: @Xtalks
Instagram: @Xtalks
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured

In this episode, Joseph Goldberg, MD, and Greg Mattingly, MD, discuss the role of antidepressants in bipolar disorder. They review use of newer antidepressants (eg, vortioxetine, vilazodone) for bipolar depression despite lack of large, formal studies for that indication, the safety/efficacy of antidepressants for bipolar II vs bipolar I, antidepressant monotherapy in bipolar II depression, ketamine/esketamine for bipolar depression, and discuss the role for an antidepressant for bipolar depression in the absence of mixed features.  

Podcast from Clinical Care Options (CCO) with Joseph Goldberg, MD, and Greg Mattingly, MD, on the role of antidepressants in bipolar disorder.

Presenters:

Joseph Goldberg, MD
Clinical Professor of Psychiatry
Department of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, New York

Greg Mattingly, MD
Associate Clinical Professor
Psychiatry, Psychopharmacology
Washington University School of Medicine
St Louis, Missouri
President
St Charles Psychiatry Associates
St Charles, Missouri  

Link to full program:
https://bit.ly/3syJzh2

In this episode, Leslie Citrome, MD, MPH, and Manpreet K. Singh, MD, MS, discuss diagnosing unipolar vs bipolar depression. They review why it can be difficult to differentiate between unipolar and bipolar depression; which screening tools they employ, including the rapid mood screener (RMS); how to reduce chances of missing mania; and special tips for differentiating between major depressive disorder (MDD) and bipolar depression in children.  

Presenters:

Leslie Citrome, MD, MPH
Clinical Professor
Department of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York

Manpreet K. Singh, MD, MS
Associate Professor of Psychiatry and Behavioral Sciences
Stanford University
Stanford, California

Link to full program:
https://bit.ly/3syJzh2